Skip to main
SVRA
SVRA logo

Savara (SVRA) Stock Forecast & Price Target

Savara (SVRA) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 44%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Savara Inc. is progressing towards the submission of its Biologics License Application (BLA) for molgramostim, which targets autoimmune pulmonary alveolar proteinosis (aPAP), a rare respiratory disease. The company anticipates that approximately 85% of the estimated 3,600 diagnosed aPAP patients will be eligible for treatment at launch, indicating a substantial potential patient base. Additionally, the strong engagement shown by patients, with 100% participation in the 96-week open-label period of the IMPALA-2 study, suggests considerable interest in the product, enhancing the company's market prospects and overall outlook.

Bears say

Savara Inc reported a net loss of $24.2 million, or $0.11 per share, for the third quarter of 2024, highlighting ongoing financial challenges. Key concerns driving a negative outlook include the risks associated with potential failure to secure regulatory approval, the possibility of a smaller than expected commercial opportunity due to market size, competition, and pricing pressures, as well as uncertainties surrounding future clinical study outcomes. Additionally, there is noted physician reluctance regarding patient testing, further impacting the prospects for successful product adoption and revenue generation.

Savara (SVRA) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 44% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Savara and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Savara (SVRA) Forecast

Analysts have given Savara (SVRA) a Buy based on their latest research and market trends.

According to 9 analysts, Savara (SVRA) has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Savara (SVRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.